• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Technology·AIFF
Held by 1 Guru
Share

Firefly Neuroscience, Inc. Stocks

$ 0.75Last Updated 20.11.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 11.97M

$ 0.75
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.0%+0.00%

Latest news

28.09.2026 16:02

Brain-scan firm Firefly to promote partner pediatric ADHD treatment; stock soars 70%

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected by mental illnesses and neurological disorders. Its flagship product, Brain Network Analytics, is a sophisticated software platform engineered to aid in the diagnosis and treatment of a diverse range of cognitive and psychiatric conditions. These conditions encompass, but are not limited to, depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. Firefly Neuroscience, Inc. caters to both pharmaceutical companies and medical practitioners.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.11.2026 15:01

Why Oil Isn't What It Seems

21.11.2026 17:01

Small caps last week: Russell 2000 outpacing S&P 500 YTD, Sellas cancer vaccine trial

21.11.2026 13:01

Will Anthropic Follow in SpaceX's Footsteps? GTA Breaks Records, and People in the U.S. Are Stocking Up on Generators

21.11.2026 04:27

Big Short hero Michael Burry takes profit amid market rout. What did he sell?

21.11.2026 04:15

The Goldman Sachs Market Panic Index pointed to continued sell-offs next week

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026